KAPA

Company Overview — What Does Kairos Pharma, LTD. Do?

We are a clinical-stage biopharmaceutical company advancing therapeutics for cancer patients that are designed to overcome key hurdles in immune suppression and drug resistance. These therapeutics include antibodies and small molecules for the treatment of prostate cancer, lung cancer, breast cancer and glioblastoma. We are driven by innovative science to develop novel and transformative drug therapies to treat cancer. Our mission is to advance our portfolio of innovative therapeutics to transform the way cancer is treated. We have leveraged molecular insights to develop a new class of novel drugs that we expect will target drug resistance and checkpoints of immune suppression. “Checkpoints” refer to molecules on certain immune cells that need to be activated (or inactivated) to start an immune response. Our portfolio of seven drug candidates offers diversification and mitigates the overall exposure to many of the inherent risks of drug development. Our key patents are licensed from Cedars-Sinai Medical Center, the largest academic medical center in the Western United States, and Tracon Pharmaceuticals, Inc., a clinical stage public biopharmaceutical company based in California. The science underlying the patents was developed at Cedars-Sinai Medical Center and was licensed to us from this institution. The human immune system can tell the difference between normal cells in the body and those it sees as “foreign,” which allows it to focus an attack on the foreign cells while leaving the normal cells alone. To do this, our immune system uses checkpoints. Cancer cells can find ways to use these checkpoints to avoid being attacked by the immune system. We are developing small molecules that we believe can specifically target these central checkpoints. In addition, we are developing an activated T cell therapy that is designed to transform a patient’s T cells into killer activated T cells against cancerous stem cells. These activated T cells are induced to target several antigen targets on glioblastoma cancer stem cells, the initiators and propagators of glioblastoma tumors. In June 2021, Kairos acquired Enviro Therapeutics, Inc., a California corporation (“Enviro”), through a share exchange. Enviro’s shareholders exchanged 100% of the outstanding shares of Enviro for 6,000,000 shares of newly issued restricted shares of common stock of Kairos. After the closing, Enviro became a wholly owned subsidiary of Kairos. The acquisition allowed us to incorporate into our company Enviro’s advanced pipeline of drug candidates in Phase 1 and Phase 2 trials. The pipeline includes two therapeutic agents addressing what we believe to be significant unmet needs in the prostate and lung cancer markets and that we believe can help address cancer progression in those cancers that develop resistance to standard therapies. Our drug candidate portfolio currently consists of a pipeline of seven drug candidates, including KROS drugs, which are immunotherapeutics, and ENV antibodies, which are designed to reverse drug resistance that often results as a consequence of the use of cancer therapeutics. Our pipeline is summarized below: . Five pre-clinical or clinical-trial stage drug candidates developed by us and designed to target immune response, including KROS 101, 102, 201, 301, and 401, which are designed to reverse immunosuppression of T cells that is caused by cancer. - KROS 101 and 102 are small molecules that are agonist and antagonist for the GITR (glucocorticoid induced TNF-like receptor) ligand, which respectively promote and inhibit T cell growth and function. GITR is a checkpoint central to control the numbers of T cells of the immune system. These molecules are in the preclinical stage and are being developed for clinical trials. - KROS 201 is an autologous T cell therapy targeting cancer stem cells of glioblastoma. This therapy has received an IND from the FDA for clinical trial and is undergoing preparation for a Phase 1 clinical trial for patients with recurrent glioblastoma. - KROS 301 is a small molecule that targets the NF-ĸß pathway, a cancer growth and immune suppressive molecule in triple negative breast cancer. This molecule is in preclinical testing. - KROS 401 is a cyclic peptide which inhibits the IL-4 and IL-13 (cytokines that play a critical role in the suppression of T cells by macrophages at the site of the tumor) receptor and is designed to reverse the immunosuppression induced by macrophages in the tumor microenvironment. . Two therapeutic agents developed by our Enviro subsidiary and designed to increase anti-tumor response in conjunction with cancer therapies by addressing resistance to these agents. - ENV 105 is an antibody that targets CD105 / Endoglin which is expressed in tumor cells and surrounding cells as the tumor becomes resistant to therapeutics in prostate cancer and lung cancer. This therapy is being tested in a randomized multicenter Phase 2 trial for prostate cancer and a Phase 1 trial in lung cancer, both of which began enrolling patients in September 2023. ENV 105 has received an IND from the FDA. - ENV 205 is an antibody that targets mitochondrial DNA which is elevated as patients become resistant to chemotherapies. This therapy is in preclinical testing. As of the date of this prospectus, our product candidates have not been approved as safe or effective by the FDA or any other comparable foreign regulator. Kairos Pharma, Ltd. was originally incorporated on June 17, 2013 under the laws of the State of California as NanoGB13, Inc. We changed our name to “Kairos Pharma, Ltd.” on July 15, 2016. On May 10, 2023, we filed a certificate of conversion with the Secretary of State of the State of California and, on the same date, we also filed with the Secretary of State of the State of Delaware a certificate of conversion from a non-Delaware corporation to a Delaware corporation pursuant to the Delaware General Corporation Law. In addition, on May 10, 2023, we also filed a certificate of incorporation with the Secretary of State of the State of Delaware and became a Delaware corporation. Our registered corporate address is 2355 Westwood Blvd., #139, Los Angeles, California. Kairos Pharma, LTD. (KAPA) is classified as a micro-cap stock in the Healthcare sector, specifically within the Pharmaceutical Products industry. The company is led by CEO John S. Yu, headquartered in LOS ANGELES, California. With a market capitalization of $12M, KAPA is one of the notable companies in the Healthcare sector.

Kairos Pharma, LTD. (KAPA) Stock Rating — Avoid (April 2026)

As of April 2026, Kairos Pharma, LTD. receives a Avoid rating with a composite score of 27.8/100 and 1 out of 5 stars from the Blank Capital Research quantitative model.KAPA ranks #3,940 out of 4,446 stocks in our coverage universe. Within the Healthcare sector, Kairos Pharma, LTD. ranks #677 of 838 stocks, placing it in the lower half of its Healthcare peers. The rating is generated by a multi-factor model that weighs quality (30%), momentum (25%), value (15%), investment (10%), stability (10%), and short interest (10%).

KAPA Stock Price and 52-Week Range

Kairos Pharma, LTD. (KAPA) currently trades at $0.58. The stock gained $0.02 (4.2%) in the most recent trading session. The 52-week high for KAPA is $2.11, which means the stock is currently trading -72.4% from its annual peak. The 52-week low is $0.40, putting the stock 45.8% above its annual trough. Recent trading volume was 26K shares, suggesting relatively thin trading activity.

Is KAPA Overvalued or Undervalued? — Valuation Analysis

Kairos Pharma, LTD. (KAPA) carries a value factor score of 14/100 in the Blank Capital model, signaling premium valuation that prices in significant future growth. The price-to-book ratio stands at 2.00x, versus the sector average of 2.75x.

At current multiples, Kairos Pharma, LTD. trades at a premium to most Healthcare peers. This elevated valuation may be justified if the company can sustain above-average growth rates and profitability, but it also creates downside risk if earnings disappoint expectations.

Kairos Pharma, LTD. Profitability — ROE, Margins, and Quality Score

Kairos Pharma, LTD. (KAPA) earns a quality factor score of 27/100, signaling below-average profitability metrics relative to the broader market. The return on equity (ROE) is -80.9%, compared to the Healthcare sector average of -43.5%, which is below typical expectations for high-quality companies. Return on assets (ROA) comes in at -78.4% versus the sector average of -33.1%.

Profitability is below benchmark levels, which may reflect industry headwinds, elevated reinvestment, or structural challenges.

KAPA Debt, Balance Sheet, and Financial Health

Kairos Pharma, LTD. has a debt-to-equity ratio of 3.0%, compared to the Healthcare sector average of 32.0%. The low leverage indicates a conservative balance sheet with significant financial flexibility. The current ratio is 27.07x, indicating strong short-term liquidity. Total debt on the balance sheet is $0. Cash and equivalents stand at $6M.

KAPA has a beta of 0.40, meaning it is less volatile than the S&P 500, making it a relatively defensive holding. The stability factor score for Kairos Pharma, LTD. is 42/100, reflecting average volatility within the normal range for its sector.

Kairos Pharma, LTD. Revenue and Earnings History — Quarterly Trend

In TTM 2026, Kairos Pharma, LTD. reported revenue of $0 and earnings per share (EPS) of $-0.30. Net income for the quarter was $-5M. Operating income came in at $-5M.

In FY 2025, Kairos Pharma, LTD. reported revenue of $0 and earnings per share (EPS) of $-0.30. Net income for the quarter was $-5M. Operating income came in at $-6M.

In Q3 2025, Kairos Pharma, LTD. reported revenue of $0 and earnings per share (EPS) of $-0.07. Net income for the quarter was $-1M. Operating income came in at $-1M.

In Q2 2025, Kairos Pharma, LTD. reported revenue of $0 and earnings per share (EPS) of $-0.08. Net income for the quarter was $-1M. Operating income came in at $-1M.

Over the past 8 quarters, Kairos Pharma, LTD. has experienced revenue contraction from $0 to $0. Investors analyzing KAPA stock should weigh these quarterly trends alongside the valuation and quality metrics discussed above.

KAPA Dividend Yield and Income Analysis

Kairos Pharma, LTD. (KAPA) does not currently pay a dividend. This is common among smaller companies in the Pharmaceutical Products industry that prefer to reinvest cash flows into business expansion rather than returning capital to shareholders. Income-focused investors looking for Healthcare dividend stocks may want to explore other Healthcare stocks or use the stock screener to filter by dividend yield.

KAPA Momentum and Technical Analysis Profile

Kairos Pharma, LTD. (KAPA) has a momentum factor score of 17/100, signaling weak relative price performance. Stocks with low momentum scores have historically tended to continue underperforming in the near term. The investment factor score is 25/100, which measures capital allocation efficiency and asset growth patterns. The short interest score of 67/100 reflects moderate short selling activity.

KAPA vs Competitors — Healthcare Sector Ranking and Peer Comparison

Within the Healthcare sector, Kairos Pharma, LTD. (KAPA) ranks #677 out of 838 stocks based on the Blank Capital composite score. This places KAPA in the lower half of all Healthcare stocks in our coverage universe. Key competitors and sector peers include ASTRAZENECA PLC (AZN) with a score of 61.4/100, Sol-Gel Technologies Ltd. (SLGL) with a score of 56.6/100, VIEMED HEALTHCARE, INC. (VMD) with a score of 53.4/100, Innoviva, Inc. (INVA) with a score of 52.7/100, and JOHNSON & JOHNSON (JNJ) with a score of 51.7/100.

Comparing KAPA against the S&P 500 benchmark is also instructive for understanding relative performance. Investors can view the full KAPA vs S&P 500 (SPY) comparison to assess how Kairos Pharma, LTD. stacks up against the broader market across all factor dimensions.

KAPA Next Earnings Date

No upcoming earnings date has been announced for Kairos Pharma, LTD. (KAPA) at this time. Check the earnings calendar for the latest scheduling updates across all stocks in our coverage universe.

Should You Buy KAPA? — Investment Thesis Summary

The quantitative profile for Kairos Pharma, LTD. suggests caution. The quality score of 27/100 flags below-average profitability. The value score of 14/100 indicates premium valuation. Momentum is weak at 17/100, a headwind for near-term performance.

In summary, Kairos Pharma, LTD. (KAPA) earns a Avoid rating with a composite score of 27.8/100 as of April 2026. The rating is derived from the Blank Capital Research methodology, which combines six factor dimensions into a single quantitative ranking. Investors should consider these quantitative signals alongside their own fundamental research, risk tolerance, and investment time horizon before making buy or sell decisions on KAPA stock.

Related Resources for KAPA Investors

Explore more research and tools: KAPA vs S&P 500 comparison, top Healthcare stocks, stock screener, our methodology, quality factor explained, value factor explained, momentum factor explained. Compare KAPA head-to-head with peers: KAPA vs AZN, KAPA vs SLGL, KAPA vs VMD.